CJC-1295/Ipamorelin Dosing Schedule
There are no FDA-approved dosing guidelines or established clinical practice guidelines for CJC-1295 (non-DAC) combined with ipamorelin in healthy adults, and these peptides remain investigational agents without regulatory approval for routine use.
Evidence Base and Regulatory Status
The available evidence consists entirely of early-phase research studies in controlled settings, not clinical practice guidelines:
CJC-1295 was studied as a long-acting GHRH analog in healthy adults at single doses ranging from 30–60 mcg/kg subcutaneously, producing sustained GH and IGF-I elevations for 6–11 days after a single injection 1
The estimated half-life of CJC-1295 was 5.8–8.1 days, with evidence of cumulative effects after multiple doses 1
In animal models, once-daily administration of 2 mcg CJC-1295 was required to maintain normal growth, while dosing every 48–72 hours proved less effective 2
Ipamorelin was characterized as a selective GH secretagogue in preclinical studies, with ED50 values of 2.3 nmol/kg in swine and demonstrated specificity for GH release without affecting ACTH or cortisol 3
In rat studies, ipamorelin was administered at 18–450 mcg/day divided into three daily doses, producing dose-dependent increases in longitudinal bone growth 4
Critical Limitations and Safety Concerns
No human clinical trials have evaluated the combination of CJC-1295 with ipamorelin, and neither agent has completed Phase III trials or received regulatory approval for any indication.
Specific Concerns:
- CJC-1295 has been identified in illicit pharmaceutical preparations and is classified as a prohibited substance under WADA Section S2 due to performance-enhancing potential 5
- The longest published human study duration was 49 days, providing no data on long-term safety, optimal dosing intervals, or chronic adverse effects 1
- All available human data come from small, short-duration Phase I/II studies in controlled research settings 1
- There are no established monitoring protocols, dose titration algorithms, or management guidelines for adverse effects in clinical practice
Research-Based Dosing Patterns (Not Clinical Recommendations)
The published research studies used the following experimental protocols:
CJC-1295 Monotherapy:
- Single doses: 30–60 mcg/kg subcutaneously produced sustained GH elevation for 6+ days 1
- Multiple dosing: Weekly or biweekly administration maintained elevated IGF-I for up to 28 days 1
- Animal data suggested daily dosing was required for optimal growth effects 2
Ipamorelin Monotherapy:
- Rat studies: 18–450 mcg/day divided into three daily doses 4
- Swine studies: ED50 of 2.3 nmol/kg for GH release 3
Clinical Practice Reality
In the absence of FDA approval, established guidelines, or adequate safety data, prescribing these peptides outside of approved clinical trials cannot be supported by evidence-based medicine principles. The provided evidence documents only early-phase research pharmacology, not clinical practice standards.
Common Pitfalls:
- Assuming research dosing protocols translate directly to clinical practice without Phase III trial validation
- Combining two investigational agents without interaction studies or safety data
- Lacking established monitoring parameters for long-term adverse effects
- Using peptides obtained from unregulated sources, which may contain unknown contaminants 5
- Absence of reversal agents or established management protocols for adverse events
Any use of these peptides should occur only within IRB-approved clinical research protocols with appropriate informed consent, safety monitoring, and regulatory oversight.